Literature DB >> 11949754

HER2/neu in the management of invasive breast cancer.

Funda Meric1, Mien-Chie Hung, Gabriel N Hortobagyi, Kelly K Hunt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11949754     DOI： 10.1016/s1072-7515(02)01121-3

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  9 in total

1.  Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Authors:  Jashodeep Datta; Cinthia Rosemblit; Erik Berk; Lori Showalter; Prachi Namjoshi; Rosemarie Mick; Kathreen P Lee; Andrew M Brod; Rachel L Yang; Rachel R Kelz; Elizabeth Fitzpatrick; Clifford Hoyt; Michael D Feldman; Paul J Zhang; Shuwen Xu; Gary K Koski; Brian J Czerniecki
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

2.  Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.

Authors:  N Cabioglu; A A Sahin; P Morandi; F Meric-Bernstam; R Islam; H Y Lin; C D Bucana; A M Gonzalez-Angulo; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

3.  Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.

Authors:  So Hee Kim; Kim Zukowski; Raymond F Novak
Journal:  Anticancer Res       Date:  2009-04       Impact factor: 2.480

4.  Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division.

Authors:  I A Akimov; E L Chernolovskaya; Yu E Spitsyna; E I Ryabchikova; M A Zenkova
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

5.  Malignant transformation of rat kidney induced by environmental substances and estrogen.

Authors:  Susana Alfaro-Lira; María Pizarro-Ortiz; Gloria M Calaf
Journal:  Int J Environ Res Public Health       Date:  2012-05-04       Impact factor: 3.390

6.  AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.

Authors:  Teraneh Z Jhaveri; Juhyung Woo; Xiaobin Shang; Ben Ho Park; Edward Gabrielson
Journal:  Oncotarget       Date:  2015-06-20

7.  Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Authors:  Jashodeep Datta; Erik Berk; Shuwen Xu; Elizabeth Fitzpatrick; Cinthia Rosemblit; Lea Lowenfeld; Noah Goodman; David A Lewis; Paul J Zhang; Carla Fisher; Robert E Roses; Angela DeMichele; Brian J Czerniecki
Journal:  Breast Cancer Res       Date:  2015-05-23       Impact factor: 6.466

Review 8.  Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Authors:  Nadia F Nocera; M Catherine Lee; Lucy M De La Cruz; Cinthia Rosemblit; Brian J Czerniecki
Journal:  Front Pharmacol       Date:  2016-10-06       Impact factor: 5.810

9.  Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

Authors:  S Sutherland; S Ashley; D Miles; S Chan; A Wardley; N Davidson; R Bhatti; M Shehata; H Nouras; T Camburn; S R D Johnston
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.